Luspatercept in the Management of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Blood Disorders

By
Xiangke Xin
Wenli Zhang
Zhen Li
Ruirui Gui
Juan Wang
Liyun Ji
Yanli Zhang
Baijun Fang
Yongping Song
Yingling Zu
Jian Zhou
February 5, 2025

Blood Cancer Journal

Objective:

To report the efficacy and safety of luspatercept in treating anemia following allo-HSCT, emphasizing the retrospective nature of the study.

Key Findings:

Include the statistical significance of the overall survival rate.

Interpretation:

Luspatercept effectively improved hemoglobin levels and erythroid response in patients with anemia following allo-HSCT, with a favorable safety profile, suggesting potential clinical implications.

Limitations:

Mention potential biases inherent in retrospective studies.

Conclusion:

Luspatercept shows promise as a treatment for anemia post-allo-HSCT, warranting further investigation in larger cohorts and diverse anemia types, particularly focusing on specific research directions.

Luspatercept in the Management of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Blood Disorders

Objective:

Key Findings:

Interpretation:

Limitations:

Conclusion:

Original Source(s)

Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases

Related Content

Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion-Dependent β-Thalassemia

Correction to: “The Beneficial Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Anemia in Type 2 Diabetes-A Real-World Study”

Temporal variation in nutritional status and preoperative anemia among patients with retroperitoneal soft tissue sarcoma: a retrospective longitudinal cohort study